Investors

Data Presentations

Data Presentations

Congress Date	Title	Authors
Presented at ASN Kidney Week 2019	Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia	A. Zuk, Z. Si, S. Loi, S. Bommegowda, S. Danthi, G. Molnar, M. Rabinowitz
Presented at ASN Kidney Week 2019	Effect of Moderate Hepatic Impairment on Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF PHI)	A. Chavan, S. Paulson, L. Burke, R. Sawant, B. Schwartz, E. deGoma
Presented at the Annual Meeting of JSN 2019	Efficacy and Safety of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, Being Evaluated for the Treatment of Anemia Due to Chronic Kidney Disease (CKD) in Japanese Subjects: Results from Phase 2 Studies (encore)	Y. Komatsu, Z. Khawaja, W. Luo, D. Vargo, Y. Farag, E. deGoma, M. Nangaku
Presented at NKF Spring Clinical Meetings 2019	Targeted Review of the Epidemiology and Burden of Anemia in Chronic Kidney Disease	M. Anatchkova, A. Brooks, A. Earley, E. Michalopoulos, G. Shafai, A. Bozas, Y. Farag, M. Sanon
Presented at NKF Spring Clinical Meetings 2019	Targeted Literature Review of Patient-reported Burden of Anemia in Chronic Kidney Disease	M. Anatchkova, M. Arregui, A. Brooks, E. Michalopoulos, G. Shafai, A. Bozas, Y.Farag, M. Sanon
Presented at NKF Spring Clinical Meetings 2019	A Review of Cost-effectiveness Analyses for Anemia in Chronic Kidney Disease	T. Lavelle, E. Michalopoulos, N. Margaretos, F. Berklein, G. Shafai, A. Bozas, M. Sanon
Presented at ASN Kidney Week 2018	Randomized, Placebo-Controlled Phase 2 Trials of Vadadustat (AKB-6548), an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), to Treat Anemia of Chronic Kidney Disease (CKD)	M. Nangaku, Z. Khawaja, W.Luo, S. Garafola, E. deGoma, Y. Komatsu
Presented at World Congress of Nephrology (WCN) 2017	Rationale and Design of the PRO2TECT Global Phase 3 Studies of Vadadustat for the Treatment of Anemia in Patients with Non-Dialysis-Dependent Chronic Kidney Disease	P. Pergola; B. Spinowitz; M. Weir; J. Tumlin; R. Agarwal; M. Nangaku; Q. Zuraw; E. deGoma; A. Sharma; B. Maroni; G. Block
Presented at NKF Spring Clinical Meetings 2017	The INNO2VATE Phase 3 Program of Vadadustat for Treatment of Anemia in Dialysis-Dependent CKD: Rationale and Study Design	W. Winkelmayer, G. Block, G. Chertow, S. Fishbane, Y. Komatsu, P. McCullough, P. Pergola, C. Rosenberger, D. Williamson, J. Yee, A. Collins, Z. Khawaja, A. Sharma, Q. Zuraw, B. Maroni
Presented at ASN Kidney Week 2016	Efficacy and dose requirements of vadadustat are independent of systemic inflammation and prior erythropoiesis-stimulating agent (ESA) dose in patients with non-dialysis dependent chronic kidney disease (NDD CKD)	V. Haase, B. Spinowitz, P. Pergola, Z. Khawaja, Q. Zuraw, A. Sharma, B. Maroni

Print Page

Email Page

Contact IR

Email Alerts

Tear Sheet

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098 phone
+1 617.871.2099 fax